Intra-Cellular's checkered developmental path ends in schizophrenia approval, shares skyrocket
It may be almost the end of the year, but the FDA’s stamina for approvals has persevered.
On Monday, Intra-Cellular Therapies secured the regulator’s blessing for its antipsychotic drug, Caplyta, despite two late-stage schizophrenia studies that left much to be desired. But as is custom with most antipsychotics, trials that fall short typically do not necessarily deter a drug’s path to approval.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 83,100+ biopharma pros reading Endpoints daily — and it's free.